Markets
President Trump Holds "Make America Wealthy Again Event" In White House Rose Garden
(Chip Somodevilla/Getty Images)

Court ruling on tariffs injects more uncertainty into already volatile US trade policy

Analysts warned that an eventual ruling could take many months, and that the Trump administration may pursue other ways of generating tariff-related income in the meantime.

A United States Court of Appeals ruling that much of President Donald Trump’s tariff regime is unlawful didn’t create any immediate market waves, if for no other reason than it’s an affirmation of what investors have been living in for most of this year: a world where the rules surrounding cross-border commerce are completely in flux.

“Confusion continues throughout supply chains as courts slowly reduce policy uncertainty but deepen operational indecision,” Kim Wallace, senior managing director at 22V Research, wrote. “Caught between optimism and prudent planning, governments negotiating with the Trump administration, businesses facing constant adjustments, and supply-chain financiers and managers, all operate in a no-guidance environment punctuated by sporadic social media posts.”

Lori Calvasina, chief US equity strategist at RBC Capital Markets, said a number of companies, including Goldman Sachs, Paccar, Hamilton Lane, Movado Group, Bath & Body Works, and Burlington Stores, had flagged the potential for court rulings to inject some additional volatility into the tariff regime over the past two reporting periods.

“We think corporate uncertainty around tariffs will remain elevated, though lower than late spring levels,” Calvasina wrote. “One of our biggest takeaways from 2Q25 reporting season was that companies continued to view the tariff backdrop as dynamic, evolving, and uncertain, despite the general dialing down of tariff levels from those announced April 2nd.”

More uncertainty has its pluses — like the potential for lower costs in the event these tariffs are struck down — and its minuses, like corporate decision-making being hamstrung in the interim.

“It has seemed clear to us, since we heard the President outline his vision in a speech to the financial community a year ago, that tariffs are a core belief of the current administration and we think it makes sense to assume that tariffs, one way or another, are likely to remain a part of the US equity market backdrop for the foreseeable future,” she concluded.

Unfortunately, whether tariffs enacted by the Trump administration as part of the International Emergency Economic Powers Act (IEEPA) run afoul of the law or not may remain an open question for a prolonged period, per George Pollack, senior US policy analyst at Signum Global Advisors.

The most likely scenario, in his view, is that the Supreme Court elects to hear the case but rules in favor of any request by the federal government to keep these levies in place until it makes its final ruling, which he warns could take until the middle of next year. Pollack’s base case is that the nation’s top court will ultimately find that these tariffs were illegal, at which point the administration would need to issue retroactive refunds for tariffs paid.

Angst in US stocks on Tuesday morning appears to be more a function of the weakness in global bond markets. The court’s ruling does introduce some crosscurrents for fixed income: in the short term, the prospect for the end of tariffs could provide inflation relief (good for bonds), but also widen the budget deficit and increase government bond supply in the event that tariff-related revenues disappear (bad). In addition, the removal of this potential economic headwind could give price pressures more staying power rather than a temporary jolt higher, which may also reduce recession risk and the likelihood of interest rate reductions by the Federal Reserve.

Grace Fan, managing director of policy research at TS Lombard, is a little more optimistic on the timeline than Pollack, judging that an eventual Supreme Court decision could come in the next three to six months.

She warns that with the future of IEEPA tariffs up in the air, “Trump will surely double down by tapping other tariff authorities, keeping trade war chaos ongoing in the next few months as tariff winners/losers shift.”

A Supreme Court ruling that IEEPA tariffs are illegal — Fan’s base case — would be a boon to big retailers like Walmart and Amazon, as well as Vietnam and select sectors in Brazil and India, in her view.

More Markets

See all Markets
markets

Applied Digital leaps on $5.2 billion deal with undisclosed US hyperscaler

Like other AI-adjacent stocks, Applied Digital has hit a bit of a speed bump of late, caught up in the malaise that sent the wider market tumbling at the end of last week. However, after unveiling a new lease agreement with an undisclosed US-based hyperscaler worth at least $5.2 billion, the stock is soaring once again today in premarket trading, up more than 11%.

The deal is with a “high investment-grade hyperscaler,” per the company’s press release, and will cover 210 MW of critical IT load at the company’s Delta Forge 2 AI Factory campus under a take-or-pay structure (in which the buyer is obliged to pay a minimum of $5.2 billion over 15 years) with renewal options.

If all renewal options are exercised, the deal would be worth approximately $12.7 billion over a 30-year total term. Initial operations at the Delta Forge 2 site are expected to commence in the first quarter of 2028.

Emphasizing the company’s “franchise model — a core team of design, construction, and operations professionals replicated across every campus, in every market,” CEO Wes Cummins noted that the latest lease is Applied Digital’s third long-term agreement with the same hyperscaler. The agreement also brings the company’s total base-term lease revenue to $36 billion, rising to $86 billion if all options are taken up.

markets

Nvidia and SK Hynix strike multiyear partnership on memory chips, AI data center build-out

Nvidia shares are modestly higher after it announced a multiyear partnership with SK Hynix on memory chips and building out AI data centers.

The agreement secures a long-term pipeline of memory chips for Nvidia. At the center of the partnership is the integration of SK Hynix’s high-bandwidth memory chips into Nvidia’s newly unveiled Vera central processing units. The Vera processor is Nvidia’s first stand-alone data center microprocessor designed to compete directly against traditional enterprise server lines.

The collaboration is also structured to reshape how semiconductors are manufactured. Under the terms of the agreement, SK Hynix will implement Nvidia’s CUDA-X library and PhysicsNeMo framework directly into its memory design and manufacturing workflows.

The announcement happened during a high-profile visit to Seoul by Nvidia CEO Jensen Huang, who arrived on June 5 to align with core infrastructure partners. Over the weekend, Huang met with SK Group Chairman Chey Tae-won, SK Hynix CEO Kwak Noh-Jung, and other top South Korean technology executives during a dinner meeting, according to Nvidia’s blog posts and Reuters.

Last week, SK Hynix told investors that its proposed US listing has received strong backing, which would potentially give US investors an alternative way to play the memory chip crunch.

markets

FuelCell Energy rises as AI data center pipeline overshadows Q2 miss

FuelCell Energy shares rebounded into positive territory during premarket trading, reversing an initial dip sparked by Q2 results that showed widening net losses and a year-over-year revenue decline.

Key numbers:

  • Revenue of $35.6 million (compared to analyst estimates of $40.56 million).

  • An adjusted loss per share of $1.45 (estimate: a $0.50 loss).

That revenue number marks a 5% decrease from the $37.4 million generated during the same quarter last year.

The company’s net loss expanded to $78.7 million, or $1.45 per share, compared to a loss of $38.8 million in the prior-year period. Management attributed the deeper loss primarily to a $42.6 million one-time impairment expense linked to essential equipment upgrades at its Groton Project facility.

While a 9.9% drop in total backlog initially added to the shares’ downward momentum, investors appeared to quickly pivot their attention to the company’s forward-looking metrics. FuelCell highlighted a 267% sequential jump in its sales pipeline, which has reached 4 gigawatts. The surge is driven by demand for its packaged 12.5-megawatt utility-grade power block solution tailored specifically for the booming AI data center market.

To support this high-growth data center strategy, FuelCell announced a major capacity expansion at its Torrington, Connecticut, manufacturing facility. The company plans to raise its annualized production ceiling from 350 MW to 500 MW, an infrastructure upgrade estimated to cost between $200 million and $275 million over the next 24 months.

Driven by the AI data center narrative, FuelCell Energy’s stock has risen over 130% year to date.

markets

Lilly says its next-gen GLP-1 shot drove 28.3% weight loss, reduced comorbidities

Eli Lilly has risen around 4% in premarket trading after reporting impressive trial results for its next-generation weight-loss drug over the weekend.

According to the results unveiled on Saturday, Lilly’s experimental weight-loss shot, retatrutide, helped patients lose 28.3% of their body weight at 80 weeks. That’s more than tirzepatide, Lilly’s weight-loss shot currently considered the most effective in the market, which helped people lose 26% of their weight over 88 weeks.

Retatrutide is a triple agonist, meaning it mimics three different hormones that promote weight loss, compared to one by Novo Nordisk’s semaglutide and two by tirzepatide. Lilly says it helps preserve more muscle mass than other weight-loss shots and also helped improve knee osteoarthritis pain and obstructive sleep apnea.

Lilly has said it would submit the drug for approval this year with the goal of getting it out to market in 2027. The jab could be the next big moneymaker for Lilly, which currently sells the most lucrative drug in the world but has had an underwhelming rollout of its oral weight-loss pill, which came to market earlier this year.

Retatrutide is already quite popular among those who experiment with peptides, or unapproved injectable drugs often sold online “for research purposes only.” For gym bros trying to attain a certain physique, a drug that has shown it can melt fat while preserving muscle is enticing.

But in a market full of knockoff drugs, will retatrutide enthusiasts pay full price for the drug when it officially goes to market?

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.